12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vacc-4x: Completed Phase II enrollment

Last month, Bionor completed enrollment of 24 HIV-infected patients stable on anti-retroviral therapy (ART) in a single-blind, placebo-controlled, Norwegian Phase II trial evaluating intranasal Vacc-4x plus ...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >